You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

p53 tumor suppressor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

p53 Gene in Metabolism Regulation in Li-Fraumeni Syndrome

Completed
  • Mitochondrial Disorders
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Nov 18, 2021

    Locally Advanced Cervical Cancer Trial in Mexico City (Curcumin, Curcumin + Piperine)

    Recruiting
    • Locally Advanced Cervical Cancer
    • Curcumin
    • Curcumin + Piperine
    • Mexico City, Mexico
      Instituto Nacional de Cancerología
    Oct 6, 2023

    Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 Trial in Worldwide (APR-246, Carboplatin and

    Completed
    Has Results
    • Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
    • APR-246
    • Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
    • Los Angeles, California
    • +54 more
    Sep 20, 2022

    High-grade Serous Ovarian Cancer Trial in Belgium, Spain, United Kingdom (APR-246, Pegylated Liposomal Doxorubicin Hydrochloride

    Completed
    Has Results
    • High-grade Serous Ovarian Cancer
    • APR-246
    • Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
    • Gent, Belgium
    • +11 more
    Jul 19, 2022

    Advanced Solid Tumor, Advanced Malignant Tumor, Metastatic Cancer Trial in United States (PC14586)

    Recruiting
    • Advanced Solid Tumor
    • +3 more
    • Los Angeles, California
    • +10 more
    Aug 12, 2022

    Solid Tumor Trial in United States (ASTX295)

    Recruiting
    • Solid Tumor
    • Duarte, California
    • +9 more
    Nov 18, 2022

    Prognostic Prediction Based on Radiomics of Giant Cell Tumor of

    Completed
    • Spinal Tumor
    • RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)
    • Beijing, Please Select An Option Below, China
      Peking University third hospital
    Jun 28, 2021

    Early Breast Cancer Three Years of More Post Primary Treatment

    Recruiting
    • Breast Cancer
    • Exercise Recall Patient Reported Outcomes
    • +10 more
    • Chapel Hill, North Carolina
      University of North Carolina
    Jun 21, 2023

    Endometrial Cancer, Serous Tumor, P53 Mutation Trial in Toronto (Cisplatin, External Beam Radiation, Carboplatin)

    Recruiting
    • Endometrial Cancer
    • +2 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    May 20, 2021

    SNPs in p53 and p53 Response Elements on Inflammatory Response

    Completed
    • HIV-1 Seropositive
    • +3 more
      • Research Triangle Park, North Carolina
        NIEHS Clinical Research Unit (CRU)
      Jan 21, 2023

      Wilms Tumor, Relapse, Death Trial in Mansoura (P53, Ki67 and Cyclin A IHC.)

      Unknown status
      • Wilms Tumor
      • +2 more
      • P53, Ki67 and Cyclin A IHC.
      • Mansoura, Dakahlia, Egypt
        Mansoura Urology and Nephrology Center. Faculty of Medicine, Man
      Feb 16, 2021

      Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations Trial in Guangzhou (Arsenic trioxide)

      Not yet recruiting
      • Pediatric Cancer
      • +2 more
      • Arsenic trioxide
      • Guangzhou, Guangdong, China
        Sun Yat-sen Memorial Hospital, Sun Yat-sen University
      Oct 12, 2023

      AML, Adult Trial in Berne (HDM201, Midostaurin)

      Terminated
      • AML, Adult
      • Berne, Switzerland
        Departement of Medical Oncology, University Hospital Berne
      Oct 3, 2022

      Solid Tumor With p53 Wild Type Status Trial in Worldwide (CGM097)

      Completed
      • Solid Tumor With p53 Wild Type Status
      • Boston, Massachusetts
      • +4 more
      Jun 10, 2021

      Solid Tumor, Lymphoma Trial in Chicago, Morristown (Ad-p53)

      Unknown status
      • Solid Tumor
      • Lymphoma
      • Chicago, Illinois
      • +2 more
      Jun 5, 2020

      Unusual Infiltrative Patterns of Malignant Cells in Endometrial

      Not yet recruiting
      • Endometrial Cancer
        • (no location specified)
        Mar 11, 2023

        Pancreas Cyst Trial in Mannheim (Next Generation Sequencing, CEA and lipase, Cytology)

        Completed
        • Pancreas Cyst
        • Next Generation Sequencing
        • +3 more
        • Mannheim, Germany
          Tertiary referral hospital: Theresienkrankenhaus und St. Hedwig
        Dec 17, 2022

        Metastatic Melanoma, Metastatic Breast Cancer, Advanced Renal Cell Carcinoma Trial in Worldwide (single arm)

        Withdrawn
        • Metastatic Melanoma
        • +5 more
        • single arm
        • (no location specified)
        Dec 20, 2022

        Glioblastoma Trial in Phoenix, Jacksonville, Rochester (BI 907828)

        Recruiting
        • Glioblastoma
        • BI 907828
        • Phoenix, Arizona
        • +2 more
        Jan 9, 2023

        Metastatic Solid Tumor Cancer, Recurrent Head Neck Cancer Trial in Houston (Ad-P53, Xeloda, Keytruda)

        Terminated
        • Metastatic Solid Tumor Cancer
        • Recurrent Head and Neck Cancer
        • Houston, Texas
          MD Anderson Cancer Center
        May 30, 2020

        Infiltrating Duct Carcinoma of the Breast

        Not yet recruiting
        • Invasive Breast Cancer
          • (no location specified)
          Jan 28, 2023

          Quantifying Systemic Immunosuppression to Personalize Cancer

          Recruiting
          • Melanoma
          • +6 more
          • MDSC quantification
          • Milan, Italy
            Fondazione IRCCS Istituto Nazionale dei Tumori
          Nov 11, 2022

          Immune Cell Response to Stimuli

          Recruiting
          • Inflammation
            • Research Triangle Park, North Carolina
              NIEHS Clinical Research Unit (CRU)
            Jan 25, 2023

            Novel MRI Techniques for Pancreatic Cancer

            Withdrawn
            • Pancreatic Ductal Adenocarcinoma
            • MRI
            • (no location specified)
            Jul 19, 2022

            Solid Tumor, Lymphoma, Peripheral T-Cell Lymphoma Trial in United States (ALRN-6924)

            Completed
            • Solid Tumor
            • +2 more
            • Birmingham, Alabama
            • +12 more
            Jul 13, 2020